Lundbeck files first application to market new antidepressant escitalopram
Danish drugmaker H Lundbeck has filed the first application formarketing approval of its new single-isomer selective serotonin reuptake inhibitor antidepressant, Cipralex (escitalopram), with the Swedish health authorities.
Sweden has been selected as the rapporteur country for the European Union mutual recognition process for Cipralex, the follow-up to the company's best-selling antidepressant Cipramil (citalopram), which is marketed in the USA by Forest Laboratories as Celexa. Forest has said it is planning to file for approval of the drug in the USA in the first half of this year.
Rapid onset and good tolerability
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze